Talk:Progressive supranuclear palsy

From Wikipedia, the free encyclopedia
Jump to: navigation, search
WikiProject Medicine / Neurology (Rated Start-class, Low-importance)
WikiProject icon This article is within the scope of WikiProject Medicine, which recommends that this article follow the Manual of Style for medicine-related articles and use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.
Start-Class article Start  This article has been rated as Start-Class on the project's quality scale.
 Low  This article has been rated as Low-importance on the project's importance scale.
Taskforce icon
This article is supported by the Neurology task force (marked as Mid-importance).
 

older talk[edit]

It should be reversed.

What should be reversed? JFW | T@lk 14:21, 20 October 2005 (UTC)

Is there any real need to have two separate articles for Progressive supranuclear palsy and Supranuclear palsy? --Bicycle repairman 17:11, 24 January 2006 (UTC)

I've merged them. JFW | T@lk 17:16, 24 January 2006 (UTC)

Rare?[edit]

A rare disease with over 10,000 sufferersin the UK alone? Rich Farmbrough 08:58 18 May 2006 (UTC).

Re:Rare?[edit]

Considering the United Kingdom has around 60 million inhabitants, that makes 1 sufferer for 6000 inhabitants. From: http://en.wikipedia.org/wiki/Rare_disease:

" A rare disease has such a low prevalence in a population that a doctor in a busy general practice would not expect to see more than one case a year. (...).

As a guide, low prevalence is taken as prevalence of less than 5 per 10,000 in the community [1].

The NIH's Office of Rare Diseases states that, "an orphan or rare disease is generally considered to have a prevalence of fewer than 200,000 affected individuals in the United States" "

Now let's see the "low prevalence": less than 5 sufferers per 10,000 inhabitants.

To reach the number of affected by PSP (which is 10,000), we have to multiply 5 per 2000:

(5 * 2000 = 10,000). And to reach the -in theory- total number of inhabitants, we do the same (10,000 * 2000 = 20,000,000).

So, in theory, there should be ten thousand sufferers for every twenty million inhabitants. As I've stated before, the United Kingdom has about sixty millions inhabitants. So, the ciphers are OK, and yeah, we can consider PSP "A rare disease with over 10,000 sufferersin the UK alone"... Which is the point I tried to prove!

adding a new ref[edit]

I tried to add a reference about Anne Turner, following the format of references in use elsewhere in the article, but couldn't get it to work. So have used a standard "cite web" and "reflist". If anyone wants to tidy this ref to make it match the others, please do so! PamD (talk) 22:09, 25 January 2009 (UTC)

later stages[edit]

I came to this article because I read an obituary of someone who had died from it. The article here, however, while clearly implying that the disease is often fatal, doesn't say much about the later stages of the disease, why it is fatal, and the mortality rate. I suppose 100% might be inferred, since the article does say that sufferers usually survive seven years after initial diagnosis. However, a little more information might help. — Preceding unsigned comment added by 96.49.86.147 (talk) 02:57, 27 May 2011 (UTC)

Rare? Definition is inconsistent between articles on neuromuscular diseases.[edit]

This article on PSP (Progressive supranuclear palsy) says it's "a rare degenerative disease", whereas the article on ALS (Amyotrophic lateral sclerosis) says it's "one of the most common neuromuscular diseases worldwide". But based on the numbers in each of the articles, it would seem that PSP is more common than ALS.

http://en.wikipedia.org/wiki/Progressive_supranuclear_palsy starts off by saying, "Progressive supranuclear palsy ... is a rare degenerative disease ... Approximately 6 people per 100,000 population have PSP." In contrast, http://en.wikipedia.org/wiki/ALS#Epidemiology says of that disease, "ALS is one of the most common neuromuscular diseases worldwide ... One or two out of 100,000 people develop ALS each year."

Of course, comparing number of people who have a disease to number of people who develop a disease each year is comparing apples and oranges. BUT the ALS article also says, "ALS is a progressive, fatal, neurodegenerative disease with most affected patients dying of respiratory compromise and pneumonia after 2 to 3 years ..." This makes it easy to estimate how many people are living with ALS. At the low end, figure one out of 100,000 people develop ALS each year, and most survive for 2 years. That's 2 people per 100,000 population. At the high end, figure two out of 100,000 people develop ALS each year, and most survive for 3 years. That's 6 people per 100,000 population.

So, a disease that afflicts between 2 and 6 people per 100,000 population is described as "one of the most common neuromuscular diseases worldwide", whereas a different disease that afflicts approximately 6 people per 100,000 population is described as "a rare degenerative disease".

http://en.wikipedia.org/wiki/Huntington%27s_disease seems an appropriate model for handling this. It just provides the numbers without editorializing. http://en.wikipedia.org/wiki/Huntington%27s_disease#Epidemiology simply says, "The worldwide prevalence of HD is 5-10 cases per 100,000 persons." So, based on that model, I've removed the word "rare" from the PSP article. — Preceding unsigned comment added by Mark Rosenthal (talkcontribs) 16:54, 21 October 2011 (UTC)

Brain review[edit]

doi:10.1093/brain/awq115 was in the external links, but should serve as a reference instead. JFW | T@lk 16:26, 28 January 2013 (UTC)

Thanks for good explanation in "Signs and symptoms" section[edit]

Someone who is very dear to me is having this. Several clarifications in parentheses makes the "Signs and symptoms" section fairly easy to read for someone with no specific medical knowledge. Thanks, good work. Paulus/laudaka Laudaka's talk page 20:01, 13 March 2013 (UTC)

Genetics and causal factors[edit]

This section needs references and is not entirely without controversy. See, e.g., http://www.ncbi.nlm.nih.gov/pubmed/10388790 - Clinical genetics of familial progressive supranuclear palsy Page Notes (talk) 00:50, 13 June 2013 (UTC)